

Haematologica
HAEMATOL/2017/173583
Version 3

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Pieterella Lugtenburg, Irit Avivi, Henriette Berenschot, Osman Ilhan, Jean Pierre Marolleau, Arnon Nagler, Antonio Rueda, Monica Tani, Mehmet Turgut, Stuart Osborne, Rodney Smith, and Michael Pfreundschuh

Disclosures: This study was sponsored by F. Hoffmann-La Roche Ltd. Editorial support under the direction of the lead author was provided by Cheryl Wright PhD and Susan Browne, PhD, of Gardiner-Caldwell Communications (Macclesfield, UK) and funded by F. Hoffmann-La Roche Ltd. P.L. has provided consultancy services for Celgene, F. Hoffmann-La Roche Ltd, MundiPharma International Ltd, Servier, and Takeda. H.B. has received personal fees and non-financial support from F. Hoffmann-La Roche Ltd. J.P.M. has received research funding from Novartis. A.R. has provided consultancy services for Celgene Corporation, Gilead Sciences, F. Hoffmann-La Roche Ltd, Janssen, and Mundipharma, and received research funding from Celgene Corporation and F. Hoffmann-La Roche Ltd. S.O. and R.S. are employees of F. Hoffmann-La Roche Ltd. M.P. has provided consultancy services for Amgen, Boehringer Ingelheim, Celgene Corporation, F. Hoffmann-La Roche Ltd, Onyx Pharmaceuticals, and Pfizer, and has received research funding from Amgen, F. Hoffmann-La Roche Ltd, and Spectrum Pharmaceuticals. I.A., O.I., M.T., and A.N. declare no competing interests.

Contributions: P.L. contributed to study design, data collection, data analysis, data interpretation, manuscript writing, and final approval of the manuscript. I.A. contributed to literature searching, data collection, data analysis, data interpretation, and manuscript writing. H.B. contributed to data collection and review of the manuscript. OI contributed to data collection, data interpretation, and manuscript writing. J.P.M. contributed to review and approval of the manuscript. A.N. contributed to patient recruitment, data analysis, and review and approval of the manuscript. A.R. contributed to data collection, data analysis, data interpretation, and writing and review of the manuscript. M.T. contributed to data analysis and data interpretation. S.O. contributed to study design, data analysis, data interpretation, and review of the manuscript. R.S. contributed to protocol development, study design, literature searching, data analysis, data interpretation, and manuscript writing and approval. M.P. contributed to study design, data analysis, and data interpretation.